At Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., we value the pursuit of scientific excellence to drive the development of new medicines and to better understand the unmet medical needs of patients suffering from Attention-Deficit/Hyperactivity Disorder (ADHD) and related conditions. We believe that great science comes from both research collaborations and independent research studies. Research studies can provide important information on the safety, efficacy, or value of medicines which helps healthcare professionals make informed decisions about their safe and proper use.

Investigator Initiated Research (IIR):

Adlon offers opportunities for Investigator Initiated Research (IIR) – which is clinical research funded by our organization, but independently developed and implemented by researchers in the United States. The design and the results of these studies will be made public through various channels including scientific publications or public websites.

Clinical Trial Opportunities

Please check back for future research opportunities.

For questions about Adlon’s IIR program and opportunities, please contact: